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ﬁlm that contributes signiﬁcantly to pathogenesis. As such, these diseases will require an innovative therapeutic
approach.We targetedDNABII proteins, an integral component of extracellular DNA (eDNA)which is universally
found as part of the pathogenic bioﬁlmmatrix to develop a bioﬁlm disrupting therapeutic. We show that a cock-
tail of monoclonal antibodies directed against speciﬁc epitopes of a DNABII protein is highly effective to disrupt
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Combining thismonoclonal antibody cocktail with a traditional antibiotic to kill bacteria newly released from the
bioﬁlm due to the action of the antibody cocktail was highly effective. Our results strongly support these mono-
clonal antibodies as attractive candidates for lead optimization as a therapeutic for resolution of bacterial bioﬁlm
diseases.
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The presence of a bacterial bioﬁlm abrogates the ability of antibodies
and antimicrobials to effectively eradicate the causative agent of many
chronic and recurrent diseases. Given that bioﬁlms are integral to the
vast majority of these diseases (Brook, 2016, Dlugaszewska et al.,
2015, Subashchandrabose and Mobley, 2015, Dou et al., 2016, Scalise
et al., 2015, Hassett et al., 2014, Swords, 2012) knowledge of the key
role of bioﬁlms in pathobiology mandates the development of ap-
proaches for therapeutic disease resolution. The list of diseases wherein
the ability to effectively disrupt bacterial bioﬁlms would be beneﬁcial is
lengthy, and ideally this would involve eradication of both themicrobes
that induce its formation as well as the recalcitrant bioﬁlm matrix. To-
wards our goal to develop a broad-based therapeutic approach for bio-
ﬁlm resolution, we focused on two common constituents of bioﬁlms
produced by multiple human pathogens, extracellular DNA (eDNA)
and a family of bacterial DNA-binding proteins called the DNABII family.
Bioﬁlms are communities of bacteria adhered to a surface with divi-
sion of labor (e.g. altered gene expression), intercellular communication
(e.g. quorum sensing), and the creation of a self-made extracellularationwide Children's Hospital,
States.
s.org (L.A. Novotny),
n),
. This is an open access article underpolymeric substance (EPS) that enshrouds and protects resident bacte-
ria (Flemming and Wingender, 2010). Often bioﬁlms arise to weather
stressful conditions, e.g. resistance to immune clearance and antibiotics
(in excess of 1000-fold greater than needed to eliminate free-living bac-
teria). Key to the bioﬁlm's protection is the extrapolymeric substance or
EPS that constitutes the bioﬁlm matrix. While themolecular makeup of
the EPS varies among bacterial species, extracellular DNA (eDNA) is a
common component (Flemming and Wingender, 2010, Fong and
Yildiz, 2015). Indeed, DNase can prevent bioﬁlm formation by multiple
pathogenic species, but does not effectively treat pre-formed bioﬁlms
despite the abundance of eDNA in mature bioﬁlms (Flemming and
Wingender, 2010). In associationwith eDNA is theDNABII family of pro-
teins which serve as lynchpin proteins, positioned at the vertices of
crossed strands of eDNA within the bioﬁlm matrix, thus contributing
to the structural stability of the bioﬁlm matrix (Goodman et al., 2011,
Idicula et al., 2016, Devaraj et al., 2015, Gustave et al., 2013).
The DNABII family is ubiquitous among eubacteria and has been
studied for almost 40 years as an intracellular architectural element.
This family is one of multiple nucleoid-associated proteins (NAPs) that
maintain the structure and function of bacterial chromatin (Swinger
and Rice, 2004). Recently, multiple labs showed that these proteins
are also abundant extracellularly (Goodman et al., 2011, Stinson et al.,
1998, Lunsford et al., 1996, Gao, 2000, Boleij et al., 2009). The DNABII
family members include integration host factor (IHF) which is a hetero-
dimer of IHFA and IHFB and histone-like protein (HU), which is a het-
ero- or homodimer of each subunit. IHF and HU have a conserved
sequence homology and as a result, a conserved architecture. Thisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(achieved by the insertion of two antiparallel β-ribbons into the DNA
minor groove that cause the DNA to bend), but also show enhanced af-
ﬁnity to pre-bent DNA structures such as cruciforms or Holliday junc-
tions (Swinger and Rice, 2004). These lynchpin proteins are present in
the bioﬁlms produced by multiple human pathogens (Goodman et al.,
2011). Further, when bioﬁlms are exposed to polyclonal rabbit antise-
rum directed against IHF isolated from Escherichia coli (anti-IHFE.coli),
complete collapse of the bioﬁlm occurs with release of resident bacteria
(Brockson et al., 2014). These observations suggested that the DNABII
proteins and eDNA might serve as universal bioﬁlm constituents that
not only contribute to structural integrity, but could also provide a
mechanism for multispecies interaction and facilitate the development
of mixed microbial bioﬁlm consortia as typically exist in nature
(Goodman et al., 2011).
Using nontypeableHaemophilus inﬂuenzae (NTHI) as amodel organ-
ism to dissect the mechanism(s) responsible for the observed complete
bioﬁlm collapse, we have shown in vitro that anti-IHFE.coli captures
DNABII proteins when they are in an ‘off’ state within the culture medi-
um (e.g.when they are not in associationwith eDNA of the bioﬁlm EPS)
(Brockson et al., 2014). This action induces an equilibrium shift that re-
sults in removal of additional DNABII proteins from the bioﬁlm matrix
(e.g. those that are in an ‘on’ state or associatedwith eDNAof the bioﬁlm
EPS), resulting in structural collapse of the bioﬁlmmatrixwith release of
the resident bacteria. These newly released bacteria were not killed by
the action of anti-IHFE.coli, however they were 4–8 fold more sensitive
to the killing action of multiple antibiotics (Brockson et al., 2014). We
have also already shown that this outcome is rapid, speciﬁc and dose-
dependent but does not require direct contact between anti-IHFE.coli an-
tibodies and the NTHI bioﬁlm (Brockson et al., 2014). Moreover, this
mechanism (which is characterized as ‘disruption’) was distinct from
the ‘dispersal’ of an NTHI bioﬁlm induced by exposure to antibodies di-
rected against the Type IV twitching pilus which mediates a distinct
‘top-down’ dispersal of the bioﬁlm that is linked to expression of the
quorum signaling molecule AI-2 (Novotny et al., 2015b).
To then determine if antibodieswith similar bioﬁlm disruption func-
tionality could be induced in vivo, we conducted a study which showed
that active immunization with IHF [now isolated speciﬁcally from NTHI
(IHFNTHI)], induced the formation of antibodies that disrupted bioﬁlms
formed by NTHI in the middle ears of chinchillas. This disruption leads
to signiﬁcantly more rapid resolution of experimental disease with
eradication of mucosal bioﬁlms (Goodman et al., 2011, Brockson et al.,
2014). Via extensive epitopemapping efforts, combinedwith additional
pre-clinical evaluation in the same chinchillamodel of experimental oti-
tis media (Goodman et al., 2011, Brockson et al., 2014), we found that
DNABII proteins that are naturally associatedwith eDNAwithin the bac-
terial bioﬁlm (as they are found in the disease state), do not induce a
protective immune response, as binding to DNA obscures the protective
epitopes within the DNABII protein. Pre-clinical studies using native
protein (with no bound eDNA) versus that which was pre-complexed
to DNA as comparative immunogens revealed that the typically ob-
scured DNA-binding tip regions of the DNABII proteins served as the
protective epitopes. We then showed that polyclonal rabbit antibodies
directed against focused 20-residue peptides which mimicked these
speciﬁc predicted protective domains within the DNA-binding tips of
IHFNTHI, were equally effective as polyclonal antisera directed against
the whole native IHFE.coli protein in terms of their ability to disrupt
bioﬁlms in vitro (Goodman et al., 2011, Brockson et al., 2014).
Having determined the mechanism of action, and shown the ability
to utilize polyclonal antibodies to disrupt bioﬁlms in vitro and also in-
duce their formation via active immunization in vivo, it was important
to ascertain the therapeutic potential of monoclonal antibodies in
order to move closer to the ability to conduct human trials. Thereby,
monoclonal antibodies directed against speciﬁc protective domains of
the DNABII protein IHF were generated in an effort to develop a lead
compound with a very speciﬁc epitope as a target. Ideally, this highlyfocused therapeutic would nonetheless provide broad protection
against diverse bacterial pathogens which shared the same or similar
targeted epitope. Thereby, in the present study, we extended our obser-
vations to determine if highly speciﬁc monoclonal antibodies (MAbs)
directed against the DNA-binding tip regions of the alpha- and beta-
subunits of IHFNTHI could individually disrupt bioﬁlms formed in vitro
by diverse strains of NTHI. In addition, we tested these MAbs against
bioﬁlms formed by four additional human pathogens: Staphylococcus
aureus, Pseudomonas aeruginosa, Burkholderia cenocepacia and
Moraxella catarrhalis. We also tested cocktails of these two MAbs both
in vitro, to determine their ability to act synergistically, and in vivo
using two distinct animal models of experimental upper and lower re-
spiratory tract diseases to determine their ability to also resolve exper-
imental infection. This outcome was achieved as evidenced by
eradication of either mucosal bioﬁlms formed by NTHI within the mid-
dle ears of chinchillas or classic multicellular aggregates of P. aeruginosa
present within the lungs of mice.
2. Materials and Methods
2.1. Peptide Design and Synthesis
To identify regions of interest within the alpha and beta subunits of
IHFNTHI, we used the known crystal structure of IHF from E. coli (Rice et
al., 1996) along with the deduced amino acid sequence of IHFNTHI to
approximate the location of the 20-mer synthetic peptides used for
the generation of MAbs (Fig. 1A). Synthesis, puriﬁcation and sequence
conﬁrmation of all synthetic peptides was performed by Ohio Peptide,
LLC.
2.2. Generation of Hybridomas, Isolation, Puriﬁcation and Validation of
MAbs
Hybridoma cell lines were generated by Rockland Immunochemical,
Inc. Brieﬂy, spleen cells from mice immunized with synthetic peptides
IhfA3NTHI, IhfA5NTHI, IhfB2NTHI or mIhfB4NTHI were fused with Sp2/0-
Ag14myeloma cells. To reduce the risk of overgrowth by non-producer
cells and ensure antibody productivity, cell lines were subcloned one or
more generations by limiting dilution. All MAbs were of the IgG1 kappa
isotype except that to peptide IhfA5 which was IgG2a/IgM kappa
isotype.
2.2.1. Culture of Hybridomas
Hybridomas were cultured in medium comprised of DMEM plus
4.5 g glucose/ml (Corning) supplemented with 2 mM L-glutamine
(Corning), 100Upenicillin-streptomycin/ml (Corning) and 2mMsodium
pyruvate (Corning). For long-term culture, hybridomas were maintained
at a density of 1 × 105 cells/ml in medium supplemented with 10%
Superlow IgG fetal bovine serum (FBS; HyClone) and 1 × 106 cells/ml
were transitioned tomediumwith 2.5% FBS formonoclonal antibody pro-
duction. After 7–10 days in FBS-limited medium, hybridomas were re-
moved from the cell culture supernatant by centrifugation and ﬁltration.
MAbs used herein were: IhfA3NTHI (clone 9B10·F2.H3); IhfA5NTHI (clone
14G8.F5.G6); IhfB2NTHI (clone 7 A4.E4.G11) and mIhfB4NTHI (clone
12E6.F8.D12.D5).
2.2.2. Puriﬁcation of MAbs
Clariﬁed cell culture supernatants were concentrated by centrifuga-
tion in Corning Spin-X UF columns (MWCO 30,000) with a ﬁnal buffer
exchange in 20 mM sodium phosphate, pH 7.0. The retentate was
then applied to a Hi-Trap Protein G column (GE Healthcare), washed
with 20 mM sodium phosphate, pH 7.0 and IgG eluted with 0.1 M gly-
cine-HCl, pH 2.7 subsequently neutralized with 1 M Tris-HCl, pH 9.0.
Antibody was dialyzed against Dulbecco's phosphate buffered saline,
pH 7.0 for 24 h at 4 °C with D-tube dialyzer MAXI (MWCO 12–14 kDa;
Novagen). The concentration of each monoclonal antibody was
Fig. 1. Design and validation of IHFNTHI tip- and tail-directed MAbs. (A) Structural models
of the IHFNTHI dimer with the predicted location of each tip- and tail-directed synthetic
peptide highlighted (black shading) as generated with PyMol software. The location of
an essential proline residue within peptides IhfA5NTHI and mIhfB4NTHI are indicated by
arrows in each model and are underlined within the respective amino acid sequences.
(B) Speciﬁcity of IHFNTHI MAbs to the synthetic peptide and IHFNTHI protein subunit
from which they were derived. Dark-colored wells within the scanned image of a
representative ELISA plate displayed reactivity of MAbs to their respective peptide and
protein subunit.
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a standard curve generatedwith BSA standards (Thermo Scientiﬁc). The
purity of each preparationwas conﬁrmed by SDS-PAGE and gels stained
with BioSafe Coomassie (BioRad) prior to imaging with Protein Simple
FluoroChem M.2.3. Cloning and Isolation of NTHI DNABII Proteins and Generation of
Polyclonal Antisera Directed Against Each
Detailed protocol for cloning and isolation of NTHI DNABII proteins
are described in Supplemental Experimental Procedures. Polyclonal
antisera against puriﬁed DNABII proteins were generated at Spring Val-
ley Laboratories (Sykesville, MD).
2.4. ELISA
To conﬁrm speciﬁcity of each monoclonal antibody, an ELISA was
performed. Synthetic peptides IhfA3, IhfA5, IhfB2 and mIhfB4 in addi-
tion to puriﬁed IHFNTHI α- and β-subunit proteins were suspended in
carbonate-bicarbonate buffer (pH 9.6), 1.0 μg added to each well of
MaxiSorp C-bottom microtiter plates (Nunc) and adsorbed for 18 h at
4 °C. Wells were then blocked with 2% bovine serum albumin (Sigma)
in 10 mM phosphate buffered saline (pH 7.4; PBS), washed with
10 mM PBS and followed by addition of 0.1 μg monoclonal antibody
per well. Wells were washed as before and goat anti-mouse IgG conju-
gated to HRP (Invitrogen; RRID AB_11180340) next added. Colour was
developed with One-Step Ultra TMB (Pierce) and the reaction stopped
with 2 M H2SO4. Assays were repeated a minimum of three times, on
separate days. A representative assay is shown in Fig. 1B.
2.5. Bioﬁlm Disruption Assay
Bioﬁlms formed by NTHI strains 86-028NP, 1714, 1885 and 214; P.
aeruginosa strain 27853; S. aureus strain 29213; Burkholderia cenocepcia
strain K56; and M. catarrhalis strain 7169 were ﬁrst established in 8-
well chambered coverglasses (Lab-Tek) for 24 h prior to treatment
(Jurcisek et al., 2011, Brockson et al., 2014) with 5 μg individual MAbs
or a cocktail containing 2.5- or 5.0-μg each MAb (tail-directed cocktail
IhfA3NTHI + IhfB2NTHI; tip-directed cocktail IhfA5NTHI + mIhfB4NTHI)
for an additional 16 h. Non-speciﬁc murine IgG1 served as a negative
control monoclonal antibody (eBiosciences; RRID AB_470112). Bioﬁlms
were thenwashed and stained with FM1-43FX bacterial cell membrane
stain (Invitrogen) to characterize the contribution of bacteria them-
selves to the bioﬁlm architecture (as opposed to other bioﬁlm matrix
materials, including eDNA) and ﬁxed overnight at 4 °C in 16% parafor-
maldehyde, 2.5% glutaraldehyde, 4.0% acetic acid in 0.1 M phosphate
buffer (pH 7.4) to prevent movement of bioﬁlms during imaging.
Bioﬁlms were viewed on a Zeiss 510 Meta-laser scanning confocal mi-
croscope, images compiledwith Zeiss Zen software and bioﬁlm biomass
calculated with COMSTAT2 software (Heydorn et al., 2000, Vorregaard,
2008). All assays were repeated a minimum of three times on separate
days.
2.6. Chinchilla Study
Thirty-six adult chinchillas (Chinchilla lanigera; 659 ± 110 g) with-
out evidence of middle ear disease or serum antibody to outer mem-
brane proteins of NTHI 86-028NP were procured from Rauscher's
Chinchilla Ranch (LaRue, Ohio) and were randomized to cohort by
weight. All animals were challenged transbullarly with 1000 CFU NTHI
strain #86-028NP per bulla delivered on a 0.3 ml volume of pyrogen-
free sterile saline to induce experimental otitis media. Four days later,
when it is known that bioﬁlms typically ﬁll ≥50% of the middle ear
space of the vastmajority of animals (in thismodel N83% of earswill de-
velop a biomass; N 67% ofwhichwill yield a score ≥ 2 on a 0 to 4+ scale)
(Novotny et al., 2011, Novotny et al., 2013b) chinchillas were randomly
grouped into cohorts of 3 animals each (6 total ears) and treatments
(MAbs or IgG-enriched polyclonal rabbit sera) assigned as detailed in
Table 1 (dosage selection process described in legend). A volume of
100 μl of each respective treatment diluted in sterile pyrogen-free ster-
ile salinewas delivered transbullarly and a total of three doses were ad-
ministered at daily intervals. One day after receipt of the ﬁnal dose,
Table 1
Cohort descriptions for three studies to assess efﬁcacy of tip and tail derived polyclonal and monoclonal antibodies.
Study Host (n) Treatment Dose
Resolution of experimental NTHI-induced
OM via treatment with polyclonal or monoclonal antibodies
Chinchilla (6) Naive rabbit serum 5.0 μg
Chinchilla (6) Rabbit anti-IHFE. coli 5.0 μg
Chinchilla (6) Rabbit anti-IHFNTHI 5.0 μg
Chinchilla (6) Rabbit anti-HUNTHI 5.0 μg
Chinchilla (6) MAb IhfA3NTHI 5.0 μg
Chinchilla (6) MAb IhfA5NTHI 5.0 μg
Chinchilla (6) MAb IhfB2NTHI 5.0 μg
Chinchilla (6) MAb mIhfB4NTHI 5.0 μg
Chinchilla (6) MAb IhfA3NTHI + IhfB2NTHI 5.0 μg each
Chinchilla (6) MAbs IhfA3NTHI + IhfB2NTHI 2.5 μg each
Chinchilla (6) MAbs IhfA5NTHI + mIhfB4NTHI 5.0 μg each
Chinchilla (6) MAbs IhfA5NTHI + mIhfB4NTHI 2.5 μg each
Clearance of P. aeruginosa from the murine
lung via delivery of MAb cocktails
Mouse (5) None None
Mouse (10) Murine IgG1 10.0 μg antibody
Mouse (10) MAbs IhfA3NTHI + IhfB2NTHI 5.0 μg each antibody
Mouse (10) MAbs IhfA3NTHI + IhfB2NTHI 5.0 μg each antibody
Clearance of P. aeruginosa from the murine
lung via delivery of MAb cocktails ± tobramycin
Mouse (5) None (sacriﬁced prior to treatment) None
Mouse (3) None None
Mouse (10) Murine IgG1 + IgG2a 5.0 μg each antibody
Mouse (13) Murine IgG1 + IgG2a + tobramycin 5.0 μg each antibody + 60 mg tobramycin/kg
Mouse (10) MAbs IhfA3NTHI + IhfB2NTHI 5.0 μg each antibody
Mouse (13) MAbs IhfA3NTHI + IhfB2NTHI + tobramycin 5.0 μg each antibody + 60 mg tobramycin/kg
Mouse (10) MAbs IhfA5NTHI + mIhfB4NTHI 5.0 μg each antibody
Mouse (13) MAbs IhfA5NTHI + mIhfB4NTHI + tobramycin 5.0 μg each antibody + 60 mg tobramycin/kg
Mouse (10) Tobramycin 60 mg tobramycin/kg
In vitro, 5 μgMAb is typically added to eachwell of a chamberside to disrupt a 24 h bioﬁlmwhich contains approx. 8 × 107 CFU NTHI per well of a chamberslide (includes both planktonic
and bioﬁlm-resident bacteria) (Brockson et al., 2014). In vivo, 4 days after TB challenge of a naive chinchilla there are approx. 108 CFU NTHI/ml MEF and ~106 CFU NTHI/mg mucosal
bioﬁlms (total of ~108 CFU/ml in themiddle ear space) (Novotny et al., 2015a). Similarly, micewere challengedwith 107 CFU of P. aeruginosa the day before administration ofMAbs. There-
by, as a ﬁrst approximation, we used what was known to be an effective dose in vitro to disrupt a bioﬁlm that contained the approximate number of bacteria we expected to be within
either the middle ear of chinchillas or lungs of mice and used this dose in our animal model systems.
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ed, serially diluted and plated on to chocolate agar to quantitate the rel-
ative bacterial load within the planktonic and adherent bioﬁlm
populations, respectively. Mucosal bioﬁlms were imaged with a Zeiss
SV6 dissecting microscope, images compiled with Zeiss Zen software
and then randomized. The relative amount of mucosal bioﬁlm that
remained within the middle ear was assessed by 5 blinded reviewers
using an established mucosal bioﬁlm scale (Novotny et al., 2011),
whereby 0=nomucosal bioﬁlm visible, 1 ≤ 25% ofmiddle ear space oc-
cluded by mucosal bioﬁlm, 2 = ≥25–50% occluded, 3 = ≥50–75% oc-
cluded, 4 = ≥75–100% occluded. All chinchilla work was performed in
accordance with state and institutional guidelines and under a protocol
approved by Nationwide Children's Hospital Institutional Animal Care
and Use Committee.
2.7. Mouse Studies
2.7.1. Delivery of MAbs Only
Thirty-ﬁvemale C57BL/6mice (approximately 8weeks of age)were
obtained from Charles River Laboratories International, Inc. and were
randomized to cohort by weight. Mice acclimated to their environment
for 5 days prior to the start of study. All mice were inoculated with
1 × 107 CFU P. aeruginosa strain 27853 (ATCC) per 0.03 ml sterile pyro-
gen-free saline by intratracheal (IT) instillation using BioLite Intubation
System (Braintree Scientiﬁc, Inc.). Twenty-four hours after IT challenge,
5 mice were sacriﬁced to obtain the baseline concentration of
P. aeruginosa per lung prior to administration of treatment (Sadikot et
al., 2007, Bjarnsholt et al., 2013, Singh et al., 2000, Bjarnsholt et al.,
2009, Bucior et al., 2013, Alemayehu et al., 2012, Fothergill et al., 2014,
Machado et al., 2011, Fu et al., 2013). Lungs were aseptically collected
and homogenized in 1.0 ml sterile saline using GentleMACs C-tubes
(Miltenyi Biotec). Lung homogenates were then serially diluted in ster-
ile saline and plated on to Trypic Soy agar (BBL). Due to the presence of
lung tissue within homogenate aliquots, agar plates were incubated for
48 h to allow sufﬁcient bacterial growth prior to enumerating the colo-
ny forming units per lung. The remaining 30 mice were randomlydivided into 3 cohorts of 10 animals each and administeredmonoclonal
antibody cocktails as described in Table 1 delivered IT in a total volume
of 0.03 ml pyrogen-free sterile saline. To assess the ability of treatment
with the IHFNTHI-targeted MAbs to reduce the bacterial load within the
lung, ﬁvemice from each cohortwere sacriﬁced 1 and 6 days after treat-
ment (2 and 7 days after P. aeruginosa challenge, respectively). Lungs
were collected, processed and homogenates plated as described. All
mouse work was performed in accordance with state and institutional
guidelines and under a protocol approved by Nationwide Children's
Hospital Institutional Animal Care and Use Committee.
2.7.2. Delivery of MAbs in Combination With Tobramycin
Eighty-seven male C57BL/6 mice (approximately 8 weeks of age)
were procured from Charles River Laboratories were randomized to co-
hort by weight and rested as before prior to IT challenge with
1 × 107 CFU P. aeruginosa strain 27853 in 0.03 ml pyrogen-free sterile
saline. One day after IT challenge and prior to receipt of any treatment,
5 mice were sacriﬁced to obtain the pre-treatment bacterial concentra-
tion within the lungs as described. An additional 3 mice were sacriﬁced
for histologic analysis as described below. The remaining 75 mice were
randomly divided in 7 cohorts of either 10 mice for monoclonal anti-
body plus tobramycin treatment (60 mg tobramycin/kg) (Sabet et al.,
2009) or 13mice for monoclonal antibody treatment alone as described
in Table 1. Murine IgG1 (eBioscience; RRID AB_470112) and IgG2a
(eBioscience; RRID AB_470115) served as negative control MAbs. One
day after receipt of treatment (two days after bacterial challenge), 5
mice from each cohort were sacriﬁced, lungs collected, homogenized
and plated as described. Also at this time point, 3 additional mice from
cohorts administered only MAb cocktails (no tobramycin) were
sacriﬁced for histologic analysis as described below. The remaining 5
mice in each cohort were sacriﬁced six days after treatment (seven
days after bacterial challenge), lungs collected and processed as de-
scribed. Mice within each cohort were randomly selected for sacriﬁce.
All mouse work was performed in accordance with state and institu-
tional guidelines and under a protocol approved by Nationwide
Children's Hospital Institutional Animal Care and Use Committee.
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At the time points described above, mice were sacriﬁced, lungs ex-
cised and inﬂated with 10% neutral buffered formalin, then embedded
in parafﬁn and sectioned at 10 μm thickness. P. aeruginosawas detected
using rabbit anti-whole Pseudomonas antibody (LifeSpan Biosciences;
RRID AB_10570660) and revealed with goat anti-rabbit IgG conjugated
to AlexaFluor 488 (Invitrogen). Lung sections were counter-stained
with DAPI (Invitrogen) and visualized using a 10× objective on a Zeiss
Axiovert 200 M inverted microscope. Images were captured with Zeiss
Axiovision software.
Immunolabled sections of lung were analyzed for the presence of
bacterial aggregates. To do so, a minimum of three 10× ﬁelds of view
(FOV) fromeach lungwere used to quantify the number of positively la-
beled P. aeruginosa aggregates per FOV. Evaluations of bacterial aggre-
gates that remained in the lungs of mice following treatment with
MAbs directed against DNABII proteins was conducted blindly.
To demonstrate the presence of bacterial eDNA, DNABII proteins and
murine neutrophils within the lungs of mice challenged IT with P.
aeruginosa, ten micron sections of parafﬁn embedded mouse lung
were deparafﬁnized, hydrated to water and incubatedwith primary an-
tibody cocktail followedby detectionwith ﬂuorescently labeled second-
ary antibodies. Bacterial eDNAandDNABII proteinswere detected using
mouse anti-dsDNA (abcam; RRID AB_470907) and rabbit anti-IHFEcoli.
Labeling by these primary antibodies was revealed with goat anti-
mouse AlexaFluor 594 (Invitrogen) and goat anti-rabbit AlexaFluor
488 (Invitrogen) respectively. Images were captured using a 63× objec-
tive on a Zeiss Axiovert 200 M inverted microscope and using Zeiss
Axiovision software.
2.9. TEM of Murine Lungs
Ten µm serial sections from the parafﬁn-embedded lungs of each
mousewere collected onto 22mmcoverglass, de-parafﬁnized, and inﬁl-
trated with LR White embedding medium (Electron Microcopy Sci-
ences, Hatﬁeld, Pa). Flat embedding in LR White was performed by
placing a gelatin capsule (with the end removed) over the tissue sec-
tion, ﬁlling with catalyzed LR White and allowed to polymerize. Thir-
ty-ﬁve nanometer sections were cut using a Leica EM UC7 ultra
microtome and collected on to a 100 mesh Formvar-coated Nickel grid
(Electron Microscopy Sciences). Contrast staining with uranyl acetate
and lead citrate was used to visualize tissue which was imaged using
an Hitachi S-4800 TSEM.
2.10. Statistical Analysis
Statistically signiﬁcant differences were calculated using GraphPad
Prism 6 (GraphPad Software, Inc.). Differences in NTHI bioﬁlm biomass
after incubation with MAbs in vitro were determined by one-way
ANOVA and Tukey's multiple comparisons test. Differences in CFU
NTHI per mg mucosal bioﬁlm and per ml middle ear ﬂuid per cohort,
and CFU P. aeruginosa per lung was calculated by Mann-Whitney test.
Resolution of mucosal bioﬁlm in vivo was analyzed by one-way
ANOVA and Tukey's multiple comparisons test. For all analyses, a p-
value ≤ 0.05 was considered signiﬁcant.
3. Results
3.1. Design of Tip- and Tail-region Peptides
Prior epitope mapping efforts using a panel of synthetic peptides to
mimic the deduced amino acid sequence of IHFNTHI as well as immune
and non-immune chinchilla sera identiﬁed functional and protective
domains positioned within the ends of the DNA-binding antiparallel
β-ribbons (e.g. the DNA-binding ‘tips’) of each IHF subunit (Goodman
et al., 2011, Brockson et al., 2014). To develop MAbs, two peptidesderived from the tip regions of IHF (IhfA5NTHI and mIhfB4NTHI) and
two derived from within the second long alpha-helix (IhfA3NTHI and
IhfB2NTHI) that is, in part, involved in dimer-dimer interactions between
the IHF subunits (e.g. the ‘tail’ regions of IHF) were used, the latter of
which served as negative controls (Fig. 1A). Both tip peptides included
an essential proline residue positioned approximately mid-sequence
(Fig. 1A, arrows) that is predicted to support the native secondary struc-
ture of the turn in the protein architecture and appears to intercalate
into DNA to facilitate or stabilize DNA bends (Rice et al., 1996).
3.2. Validation of MAb Speciﬁcity
By ELISA, all MAbs recognized the homologous peptide to which
they were targeted as well as the isolated IHF subunit from which
they were derived (Fig. 1B). Due to homology between the alpha- and
beta-subunits of IHFNTHI (47% identical, 70% similar), MAbs directed to-
wards one subunit often demonstrated some cross reactivity with the
heterologous subunit. However, there was no cross reactivity between
MAbs directed at tail peptides with tip peptides or vice versa.
3.3. Disruption of Diverse Bacterial Bioﬁlms In Vitro
To assess the ability of the IHF-directed MAbs to disrupt pre-formed
bioﬁlms, 24-h NTHI bioﬁlms were exposed to MAbs for 16 h in vitro.
NTHI #86-028NP formed a robust bioﬁlm that was undisturbed by
treatment with non-speciﬁc murine IgG1 (Fig. 2A). Incubation with
5 μg of either of the two tip-directed MAbs (IhfA5NTHI and mIhfB4NTHI)
induced a signiﬁcant 6–7-fold reduction in bioﬁlm biomass compared
to either of the two tail-directed MAbs (IhfA3NTHI and IhfB2NTHI;
p ≤ 0.0001; Fig. 2B). A cocktail of both tip-directedMAbs had an additive
effect, this degree of disruption was signiﬁcantly greater than that in-
duced by treatment with a mixture of the tail-directed MAbs
(p ≤ 0.0001) (Fig. 2A, bottom row). Comparable results were achieved
with an additional three clinical isolates of NTHI (strains #1885, 1714
and 214) (Fig. 3A & B), thus demonstrating the breadth of efﬁcacy of
the IHF tip-directed MAbs against bioﬁlms formed by diverse NTHI
strains.
To determine if these MAbs could also disrupt bioﬁlms formed by
other human respiratory tract pathogens, we repeated bioﬁlm disrup-
tion assays with M. catarrhalis (strain 7169), B. cenocepacia (strain
K56), P. aeruginosa (strain 27853) and S. aureus (strain 29213). Bioﬁlms
formed by each bacterial species within 24 h varied greatly in architec-
ture (Fig. 3C, 1st column), nevertheless tip-directed MAbs (IhfA5NTHI
and mIhfB4NTHI) were highly effective against each of these pathogens,
resulting in signiﬁcant disruption (p ≤ 0.05) (Fig. 3C, columns 3, 5 & 7
and D) whereas those directed against the tails (IhfA3NTHI and
IhfB2NTHI) were not (Fig. 3C, columns 2,4 & 6 and D).
3.4. Efﬁcacy of the Tip-directed MAbs to Resolve Experimental NTHI-in-
duced Otitis Media
To test the ability ofMAbs directed towards speciﬁc 20-mer epitopes
of the alpha and beta subunit of IHFNTHI to render a therapeutic effect in
vivo, we used a robust and highly reproducible chinchilla model of
NTHI-induced otitis media (OM) (Bakaletz, 2009) wherein OM is ﬁrst
induced by inoculation of each middle ear with NTHI. Four days later,
when it is known that NTHI bioﬁlms typically ﬁll ≥50% of the middle
ear space of the vast majority of animals (in this model N83% of ears
will develop a biomass, N67% of which will yield a score ≥ 2 on a 0 to
4+ scale) (Novotny et al., 2011, Novotny et al., 2013b), we instilled
100 μl of either: tip- or tail-directedMAb, IgG-enrichedpolyclonal rabbit
antibody against a native DNABII protein or a cocktail of MAbs as de-
tailed in Table 1 directly into the middle ear. This treatment was deliv-
ered daily for a total of three sequential days. Twenty-four hours after
receipt of the ﬁnal dose, animals were sacriﬁced and images of both
middle ears were captured by light microscopy for blinded evaluation.
Fig. 2. MAbs directed against the DNA-binding tip regions of IHFNTHI disrupted bioﬁlms formed by NTHI 86-028NP in vitro. (A) Images obtained by confocal scanning microscopy
demonstrating top-down and side views of representative 24-h bioﬁlms formed by NTHI strain #86-028NP maintained in medium, or incubated for an additional 16 h with 5 μg
murine MAbs as indicated. Bacteria within bioﬁlms were stained with FM1-43FX membrane stain (green). Images are representative of three independent experiments. Scale bars,
20 μm. (B) Mean bioﬁlm biomass ± SEM remaining after treatment as determined by COMSTAT2 analyses of three independent experiments. ***, p ≤ 0.001; ****, p ≤ 0.0001.
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ent to the middle ear mucosa or resident within mucosa-associated
bioﬁlms, IgG-enriched polyclonal rabbit antiserum to IHFE. coli, IHFNTHI
or HUNTHI induced a signiﬁcant decrease in bacterial load (1.6-, 2.0-
and 2.1-log reductions, respectively) compared to naive rabbit IgG
(p ≤ 0.01; Fig. 4A). No reduction in bacterial load was achieved with
tail-directed MAbs IhfA3NTHI or IhfB2NTHI. There was however signiﬁ-
cant 1.5- and 1.9-log reductions in those cohorts that received MAbs
to either IhfA5NTHI or mIhfB4NTHI, respectively (p ≤ 0.01). Receipt of a
cocktail of tail-directed MAbs at either of two concentrations tested
did not reduce the relative bacterial load within the middle ears. Con-
versely, a dose-dependent 0.7-log decrease in bacterial load was
shown in the two cohorts that received cocktails of tip-directed MAbs
with complete eradication of NTHI from two of these samples in the co-
hort that received the higher dose (5 μg of each MAb). This difference
was statistically signiﬁcant from those that received antibody against
puriﬁed IHFE. coli (p ≤ 0.01) and also against those cohorts that received
either of the two tail-directed MAbs individually (p ≤ 0.01), or anFig. 3. IHFNTHI tip-directed MAbs disrupted bioﬁlms formed by clinically-relevant bacterial sp
clinical isolates of NTHI revealed disruption of pre-formed bioﬁlms by incubation with th
IhfB2NTHI. (B) This observation was further quantitated as a reduction in bioﬁlm biomass by C
the bacterial pathogens M. catarrhalis, B. ceneocepacia, P. aeruginosa, and S. aureus by treatm
mean bioﬁlm biomass. Images are representative of three independent experiments. Scale barequivalent dose of a tail-directedMAb cocktail (p ≤ 0.05). For the plank-
tonic bacterial sub-population present within middle ear ﬂuids (Fig.
4B), the results were very similar to those seen for the adherent and
mucosal bioﬁlm sub-population. Again, we saw complete eradication
of NTHI from the middle ear ﬂuids of 4 ears in the cohort that received
5 μg of each MAb as a cocktail of tip-directed MAbs.
Importantly, we also quantitatively evaluated how much mucosal
bioﬁlm remained in chinchilla middle ears after receipt of treatment
using a published scoring rubric that ranks the degree towhich themid-
dle ear space is ﬁlled with bioﬁlm (where 1+= b25% ﬁlled and 4+=
≥75–100% ﬁlled) (Novotny et al., 2011). As expected due to their dem-
onstrated bioﬁlm disruption capability in vitro, all IgG-enriched rabbit
polyclonal antisera directed against a native DNABII proteinwere highly
effective, signiﬁcantly reducing NTHI bioﬁlms within the middle ear
compared to those that received naive rabbit IgG (p ≤ 0.0001) (Fig.
4C). Anti-IHFE. coli and anti-IHFNTHI appeared slightly more efﬁcacious
than anti-HUNTHI however this difference was not statistically signiﬁ-
cant. Following receipt of a single MAb, once again tail-directed MAbsecies. (A) Confocal scanning microscopy images of bioﬁlms (green) formed by multiple
e MAbs IhfA5NTHI and mIhfB4NTHI, a result not observed with the MAbs IhfA3NTHI and
OMSTAT2 analyses. (C) Representative images showed disruption of bioﬁlms formed by
ent with the IHFNTHI tip-directed MAbs and (D) quantitated as signiﬁcant reduction in
s, 20 μm. *, p ≤ 0.05.
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Fig. 4. Clearance of NTHI from the middle ear in a chinchilla model of experimental otitis media. NTHI bioﬁlms were established within the middle ears of chinchillas prior to infusion of the
middle ear space with IgG-enriched polyclonal rabbit sera or murine MAbs. (A) CFU NTHI per mg mucosal bioﬁlm and NTHI adherent to the middle ear mucosal epithelium. The limit of
detection is indicated by a dashed horizontal line. (B) Clearance of NTHI from middle ear ﬂuids. CFU NTHI in middle ear effusions after infusion of the middle ear space with IgG-enriched
polyclonal rabbit sera or murine MAbs. (C) Resolution of established NTHI bioﬁlms from the chinchilla middle ear. Images of each middle ear were blindly ranked to determine the relative
quantity of mucosal bioﬁlm that remained after infusion of the middle ear space with IgG-enriched polyclonal rabbit sera or murine MAbs. An established mucosal bioﬁlm scale was
employed (Novotny et al., 2011), whereby 0 = nomucosal bioﬁlm visible, 1 ≤ 25% of middle ear space occluded by mucosal bioﬁlm, 2 = ≥25–50% occluded, 3 = ≥50–75% occluded, 4 =
≥75–100% occluded. (D) Representative images of chinchilla middle ears after infusion of the middle ear space with IgG-enriched polyclonal rabbit sera or murine monoclonal antibodies.
The mucosal bioﬁlm score is indicated in the bottom right corner of each image. TM - tympanic membrane, S - bony septae, MEM - middle ear mucosa, B - mucosal bioﬁlm. For bar graphs,
values for each individual middle ear is shown (circles; 6 middle ears per cohort) and the mean ± SEM for the cohort presented (bars).*, p ≤ 0.05; **, p ≤ 0.01; ****, p ≤ 0.0001.
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IhfA5NTHI and mIhfB4NTHI induced signiﬁcant resolution of mucosal
bioﬁlms (p ≤ 0.0001). In concordance with bacterial load data (Figs.
4A&B), no reduction in mucosal bioﬁlm was observed in animals that
received cocktails of tail-directed MAbs regardless of the dose received.
Conversely, animals that received either the low or high dose cocktail of
tip-directed MAbs demonstrated the greatest reduction in middle ear
mucosal bioﬁlm of any of the 12 cohorts (Fig. 4C).
Representative images of middle ears from selected chinchilla co-
horts are shown in Fig. 4D. Robust bioﬁlms remained in the middle
ears of animals that received either naive rabbit IgG, tail-directed
MAbs IhfA3NTHI (Fig. 4D) or IhfB2NTHI (not shown) or the cocktail of
MAbs to the two tail peptides at either dose (lower dose shown). Con-
versely, there was little to no evidence of a mucosal bioﬁlm remaining
within the middle ears of animals treated with the tip-directed MAbsIhfA5NTHI (Fig. 4D) or mIhfB4NTHI (not shown) or the cocktail of tip-di-
rected MAbs at both doses (lower dose shown). Intriguingly, there
was also little or no evidence of any inﬂammation in the middle ears
of these latter cohorts despite the fact that four days earlier this anatom-
ical nichewas ﬁlledwith a Gramnegative bacterial bioﬁlm. Collectively,
these data demonstrated the therapeutic efﬁcacy of the tip-directed
MAbs to resolve NTHI bioﬁlms formed in the middle ear during experi-
mental OM.
3.5. Efﬁcacy of the Tip-directed MAbs to Resolve P. aeruginosa Lung
Infection in a Murine Model
To determine if the outcome seen in the chinchilla model of experi-
mental OM due to NTHI could be expanded and applied to diseases
caused by another bacterial species, we then tested the cocktail of tip-
Fig. 5. Clearance of P. aeruginosa from the lungs of mice after treatment with MAbs
directed against the DNA-binding tip regions of IHF. Mice were challenged
intratracheally with P. aeruginosa followed one day later by instillation of a cocktail of
(A) 10 μg tip-directed or tail-directed MAbs or (B) MAb cocktails ±60 mg tobramycin
per kg body weight. CFU P. aeruginosa per individual lung (5 mice per cohort) and mean
CFU P. aeruginosa ± SEM for each cohort shown (bars). *, p ≤ 0.05; **, p ≤ 0.01; ***,
p ≤ 0.001. Tobi: tobramycin.
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were challenged with P. aeruginosa #27853 by intratracheal (IT) instil-
lation, when the bacterial load in the lungs was ~8.4 × 103 CFU/lung
(Fig. 5A), a single small volume dose (0.03ml) of either nonspeciﬁcmu-
rine IgG1 (negative control) or a cocktail of tip-directedMAbs or tail-di-
rected MAbs was administered IT. At both 1 and 6 days after this
singular delivery of antibodies, micewere sacriﬁced and the lungs proc-
essed to determine relative bacterial load. Whereas at 1-day post-ther-
apy there was no difference between cohorts that received nonspeciﬁc
murine IgG1 and those that received the cocktail of tail-directed MAbs
IhfA3NTHI and IhfB2NTHI, mice administered a cocktail of tip-directed
MAbs IhfA5NTHI and mIhfB4NTHI showed a signiﬁcant N2-log reduction
in bacterial load within this 24 h period (p ≤ 0.05) (Fig. 5A). This signif-
icant difference wasmaintained for 6 days despite the fact that both the
control cohort of mice as well as those that had received the cocktail of
tail-directed MAbs had also begun to clear P. aeruginosa from the lungs
compared to pre-treatment. Nonetheless, the difference between these
two latter cohorts and those that received the tip peptide-directedMAb
cocktail remained statistically signiﬁcant (p ≤ 0.05). Moreover, thislatter cohort was the only cohort wherein several lungs yielded no
bacterial counts.
Given that treatment with antibodies directed against a DNABII pro-
tein (or derived peptide) induced collapse of the bioﬁlm with release of
viable resident bacteria, we envision a combinatorial treatment for clin-
ical evaluation wherein an effective antibiotic (or antiserum) is co-de-
livered to mediate killing of released bacteria. Thereby, we expanded
the above-described study to add tobramycin to those MAb cocktails
delivered to selected cohorts. One day after treatment, there was no
reduction in CFU P. aeruginosa per lung homogenate in animals that re-
ceived tobramycin alone despite the fact that this strain of P. aeruginosa
is susceptible to the action of this antibiotic when grown in planktonic
culture (Eckert et al., 2006). There was similarly no reduction in CFU P.
aeruginosa in cohorts that received either a cocktail of nonspeciﬁc mu-
rine IgG1 and IgG2a with or without tobramycin, or a cocktail of tail-di-
rectedMAbs with or without tobramycin or tobramycin alone (Fig. 5B).
Conversely, cohorts ofmice that received a cocktail of tip-directedMAbs
with or without tobramycin showed a signiﬁcant reduction in lung bac-
terial load compared to mice administered the cocktail of murine
IgG1 + IgG2a (p ≤ 0.01), those treated with tail-directed MAb cocktail
of IhfA3NTHI + IhfB2NTHI (p ≤ 0.05) or those treated with tobramycin
alone (p ≤ 0.05). The level of signiﬁcance among these cohorts increased
6 days after treatment. The addition of tobramycin to a cocktail of tip-di-
rected MAbs appeared to confer an added beneﬁt although all cohorts
that received this MAb cocktail generated very low or no CFU counts
in lung homogenates, thereby this differencewas not statistically signif-
icant. Again, only those cohorts that received tip-directedMAbs yielded
lungs in which bacteria had been completely eradicated.
Histological evaluation of the murine lungs revealed multiple char-
acteristic aggregates of P. aeruginosa (Bjarnsholt et al., 2013, Singh et
al., 2000, LaFayette et al., 2015) in sections of lung recovered prior to
treatment (Fig. 6A; yellow, aggregates encircled), in mice treated with
a cocktail of murine IgG1 + IgG2a (Fig. 6B) or those treated with the
cocktail of tail-directed MAbs (Fig. 6C). Multicellular aggregates were
observed dispersed throughout the lung with 7 to 15 aggregates ob-
served in any single 10× ﬁeld of view in lungs frommice prior to treat-
ment or in those cohorts treated with either murine IgG or with tail
peptide MAbs. Upon examination at higher magniﬁcation, these aggre-
gates appeared to contain a considerable number of bacterial cells along
with positively labeled extracellular proteins (Fig. 6E-G). The number of
bacterial cells within these aggregates was estimated to be 50 to 100. In
lungs of mice treated with the cocktail of MAbs directed against
IhfA5NTHI + mIhfB4NTHI, only 1 to 3 aggregates was observed within
any 10× ﬁeld of view andmost of these aggregates appeared to contain
a single bacterium (Fig. 6D&H). Positively labeled extracellular proteins
inhibited us from getting a more accurate count of bacterial cells per
large aggregate via confocal microscopy, however when examined via
TEM, N100 bacterial cells were observed in large aggregates (Fig. 6I) in
those cohorts of mice that did not clear P. aeruginosa (Fig. 6A–C). Indi-
vidual bacteria or small aggregates of P. aeruginosa characteristic of
mice treated with the tip-directed MAb cocktail (Fig. 6D & H) were
too rare to be found by TEM. Four days after the IT challenge of mice
with P. aeruginosa, bacterial eDNAwith associated proteins and neutro-
phils were observed in the lungs of mice prior to treatment (Fig. 7).
4. Discussion
ExtracellularDNAwith associatedDNABII proteins are common con-
stituents of bioﬁlms formed by a large number of human pathogens
where they contribute signiﬁcantly to the structural stability of these
fortresses that house and protect resident bacteria from host immune
effectors and the action of antimicrobials (Goodman et al., 2011). By
targeting these lynchpin proteins that are positioned at the vertices of
crossed strands of eDNA within the bioﬁlm matrix, we've shown that
we can induce complete collapse of the bioﬁlm with release of resident
bacteria without killing them (Goodman et al., 2011, Brockson et al.,
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innate and acquired immune effectors or antibiotics, towhich they have
signiﬁcantly increased sensitivity (Brockson et al., 2014). This unique
phenotype of newly released bacteria, which is distinct from thosegrowing either planktonically or resident within a bioﬁlm, has been re-
ported by others (Pettigrew et al., 2014, Chao et al., 2014) and could
provide an opportune treatment window for bioﬁlm-associated
diseases.
Whereas the efﬁcacy of this DNABII protein-targeted approach had
been demonstrated both in vitro (Goodman et al., 2011, Gustave et al.,
2013, Brandstetter et al., 2013, Novotny et al., 2013a, Brockson et al.,
2014, Devaraj et al., 2015) and in vivo (Justice et al., 2012, Novotny et
al., 2015b), the majority of the work published to date was conducted
using polyclonal rabbit antiserum directed against native IHF that was
isolated and puriﬁed from E. coli. To determine if this strategy was also
effective when IHF or HU was isolated from another human pathogen,
polyclonal antisera against these proteins as isolated and puriﬁed from
the respiratory tract pathogenNTHIwere used.Moreover, in an attempt
to move closer to a lead clinical compound, peptides that targeted func-
tional and protective domains of the alpha and beta subunit from
IHFNTHI were designed to develop MAbs to these speciﬁc 20-mer do-
mains. These MAbs were tested here both singly and admixed as cock-
tails in vitro against several human pathogens as well as in vivo, using
two unique animal models: NTHI infection of the chinchilla middle ear
or P. aeruginosa infection of the murine lung.
In vitro efﬁcacywas shown against multiple clinical isolates of NTHI;
the Gram negative cystic ﬁbrosis (CF) and burn wound pathogen P.
aeruginosa; the Gramnegative respiratory tract pathogenM. catarrhalis;
the organism responsible for deadly ‘cepacia syndrome’ in CF patients B.
cenocepacia and Gram positive S. aureuswhich is responsible for a host
of troublesome infections (Jansen et al., 2013). The ability to effectively
disrupt bioﬁlms formed by these diverse humanpathogens is attributed
to the relative conservancy of IHF among these ﬁve microbes. Members
of theDNABII family have overall modest primary sequence identity de-
spite a highly conserved secondary structure (Swinger and Rice, 2004).
In the case of these four pathogens, compared to their closest DNABII
orthologue in NTHI there is 38% to 62% overall sequence identity. How-
ever, within the DNA binding tips (from which the peptide epitopes
were derived and the MAbs directed), there is overall greater sequence
identity (e.g. 45% to 80%). Interestingly, Gram positive bacteria, includ-
ing S. aureus have a single HU allele, their only DNABII gene. Despite
its low primary sequence identity overall and between epitope tip re-
gions with NTHI, there nonetheless appears to be sufﬁcient structural
recognition for the IHFNTHI-speciﬁc MAbs to readily resolve S. aureus
bioﬁlms in vitro. This outcome suggests that it is the combination of se-
quence and subsequent structure that is critical for antibody recognition
and bioﬁlm disruption.Fig. 6. Reduction in both P. aeruginosa aggregate number and size within lungs treated
with IHFNTHI tip-directed MAbs in an experimental murine model of lung infection. (A)
Multiple bacterial aggregates were observed throughout the lungs of mice prior to
treatment (yellow, aggregates encircled) and (B) in lungs after receipt of nonspeciﬁc
murine IgG1+ IgG2a (C) or a cocktail of the tail-directed MAbs IhfA3NTHI + IhfB2NTHI.
(D) In contrast, few P. aeruginosa were detected after delivery of tip-directed MAbs
IhfA5NTHI + mIhfB4NTHI thus demonstrating the efﬁcacy of this therapeutic strategy.
DAPI counterstain (blue); scale bars, 50 μm. Panels E–H - higher magniﬁcation images of
representative aggregates for each cohort showing either relative size of the aggregates
or the presence of single bacteria [E- prior to treatment; F – treatment with nonspeciﬁc
murine IgG1 + IgG2a; G – treatment with tail-directed MAbs IhfA3NTHI + IhfB2NTHI and
H – treatment with tip-directed MAbs IhfA5NTHI + mIhfB4NTHI (P. aeruginosa aggregates
were labeled with ﬂuorescently tagged rabbit antibody to whole P. aeruginosa which
labels both the bacteria themselves as well as bacterial proteins contained within the
bioﬁlm matrix hence the inability to readily resolve individual bacterial cells)]. Note that
aggregates in Panels A, B & C and E, F & G are similar in size whereas those imaged in
lungs treated with the cocktail of tip-directed MAbs appear as single bacterial cells
(Panels D & H); scale bars, 5 μm. A representative TEM image of a P. aeruginosa
aggregate as shown in Panels A, B & C or E, F & G is presented in Panel I. Bacterial cells
are pseudo-colored green and mouse lung tissue is pseudo-colored blue to aid in
visualization. Bacterial aggregates within lungs from mice that received murine IgG or
tail-directed MAbs typically contained 50–100 bacteria. The relatively limited number of
very small clusters or presence of only single bacteria resident within lungs from mice
treated with tip-directed MAbs precluded visualization by TEM; Scale bar, 2 μm. Table:
FOV – ﬁeld of view.
Fig. 7. Detection of eDNA, DNABII protein and neutrophils within the lungs of mice after
challenge with P. aeruginosa. Lungs collected from mice 4 days after IT challenge were
embedded in parafﬁn and 10 μm sections were immunolabeled for the presence of
eDNA, DNABII protein and neutrophils. Strands of eDNA (red, Panel A) and DNABII
protein (green, Panel B) were present within the murine lung. Association between the
eDNA and DNABII proteins is shown in the merged image (Panel C) where co-
localization of eDNA and DNABII proteins appears yellow. Neutrophils appear white in
these image (refer to arrowheads in panel A). Scale bar 5 μm.
43L.A. Novotny et al. / EBioMedicine 10 (2016) 33–44We then used twomodels of bioﬁlm infections to test the in vivo ef-
ﬁcacy of these targetedMAbs and found that animals treatedwithMAbs
derived against the tip peptides of the alpha and beta subunit of IHFNTHI
resolved infection signiﬁcantly earlier than other cohorts. Notably chin-
chillas treated with tip-directed MAbs demonstrated a marked reduc-
tion or complete eradication of pre-existing mucosal bioﬁlms from the
middle ear spacewith little to no residual signs of inﬂammation. Collec-
tively these data suggested to us that in addition to the bioﬁlm disrup-
tion effect mediated by delivery of IHF-directed antibodies into the
middle ear, the host immune system also became engaged andcontributed to the eradication of NTHI likely via the action of innate
host defense peptides and phagocytosis.
Given the commonality of eDNA and associated DNABII proteins in
bioﬁlms formed bymultiple and diverse human pathogens, the efﬁcacy
achieved by delivery of MAbs that target the DNA-binding tips of these
proteins, in terms of reducing the bacterial load and/or eradicating mu-
cosal bioﬁlms, is strongly supportive of their continued development as
a lead therapeutic compound.Whereas here, we used twomodels of re-
spiratory tract diseases due to either NTHI (middle ear infection, the up-
permost reach of the respiratory tract) or P. aeruginosa (lung infection,
lower airway), the already demonstrated in vitro effectiveness of this
approach against a diverse panel of pathogens suggests that the utility
could be signiﬁcantly broader with potential application to many dis-
eases of man and animals. The transition to monoclonal antibodies di-
rected against speciﬁc targeted epitopes is important as it allows the
development of a signiﬁcantlymore focused therapeuticwith the ability
to humanize the monoclonal(s) for delivery in clinical trials; this is
ongoing.
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